Bunnell M, Zhang C, Lee C, Bianchi D W, Wilkins-Haug L
Maternal Fetal Medicine, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, USA.
Geisel School of Medicine at Dartmouth College, Hanover, NH, USA.
Prenat Diagn. 2017 Apr;37(4):416-419. doi: 10.1002/pd.5022. Epub 2017 Mar 8.
22q11.2 deletion, the most common microdeletion syndrome within the general population, is estimated to have a prevalence of 1 in 3000 to 6000. Non-invasive prenatal testing has recently expanded to include screening for several microdeletions including 22q11.2. Given the expansion of prenatal screening options to include microdeletions, it is important to understand the limits of this technology and the variety of reasons that a discordant positive result can occur. Here, we describe a case of a pregnant woman who received a positive non-invasive prenatal maternal plasma screen for 22q11.2 deletion. Maternal and postnatal neonatal peripheral blood cytogenetic, PCR, and fluorescence in situ hybridization studies were normal, but the placenta was mosaic for 22q11.2 deletion in two of three biopsy sites. This case illustrates both the complexities of pre- and post-test counseling for microdeletion screening and the potential for a discordant positive microdeletion result because of confined placental mosaicism. © 2017 John Wiley & Sons, Ltd.
22q11.2缺失是普通人群中最常见的微缺失综合征,据估计其患病率为1/3000至1/6000。非侵入性产前检测最近已扩展到包括对几种微缺失的筛查,其中就有22q11.2。鉴于产前筛查选项已扩展到包括微缺失,了解这项技术的局限性以及出现不一致阳性结果的各种原因很重要。在此,我们描述了一例孕妇,其非侵入性产前母体血浆筛查显示22q11.2缺失呈阳性。母体和产后新生儿外周血细胞遗传学、聚合酶链反应(PCR)及荧光原位杂交研究均正常,但胎盘在三个活检部位中的两个部位存在22q11.2缺失的嵌合体。该病例既说明了微缺失筛查的检测前和检测后咨询的复杂性,也显示了由于局限性胎盘嵌合体导致微缺失结果出现不一致阳性的可能性。© 2017约翰·威利父子有限公司